Colorectal cancer
Conditions
Interventions
Gold Standard:Pathological test results
Index test:Septin9 and BCAT1 gene methylation detection kit (Fluorescence PCR method)
Sponsors
Zhongshan Hospital Affiliated to Xiamen University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: A. Group of suspected cases of colorectal cancer or precancerous lesions ? Clinical doctors suggest performing colonoscopy for suspected cases of colorectal cancer or precancerous lesions. ? No history of malignant tumors, no history of radiation or chemotherapy treatment, all females are non pregnant. ? The sample type should be plasma sample, and the blood collection time should be before colonoscopy examination. ? The sample information is complete and the participants voluntarily participate in the experiment. B. Other malignant tumor groups other than colorectal cancer ? Cases of other malignant tumors diagnosed as non colorectal cancer. ? The sample type should be plasma samples, and the blood collection time should be before various cancer treatments. ? Complete sample information, voluntary participants in the trial C. Patients with no space occupying lesions in the intestine or healthy individuals ? Under colonoscopy, there were no other abnormalities except for hemorrhoids. ? Complete sample information, voluntary participants in the trial D. Cases after surgical treatment for colorectal cancer ? Preoperative samples were collected using the Septin9 and BCAT1 gene methylation combined detection kit (fluorescence PCR method) developed by Xiamen Tengji Medical Technology Co., Ltd. to detect positive cases. ? The postoperative sampling time should be scientifically set based on the development pattern of the disease and the requirements of post-treatment monitoring time. It is recommended to collect samples from patients within six months after surgery.
Exclusion criteria
Exclusion criteria: ? The sample volume does not meet the demand for comparative reagents/methods used in the assessment kit. ? The researchers believe that other reasons are not suitable for participants in this trial. ? Exclude patients who have been diagnosed with colorectal polyps, colorectal cancer, or related intestinal diseases, or have a family history of CRC.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactGuoyang Wu
Zhongshan Hospital Affiliated to Xiamen University
Outcome results
None listed